The current ESC/EAS guidelines and the ESC guidelines from 2021, the multisociety guideline on the management of blood cholesterol from 2018 as well as the ACC report from 2022 recommend PCSK9 inhibitors for very-high-risk FH patients if their treatment goal is not reached on the maximally tolerated statins plus ezetimibe, as well as in FH patients who do not tolerate statins [7,87,88,89,91]. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.